Oyster stress pathway mapped in lung cancer cells

At the Institute of Oceanology of the Chinese Academy of Sciences, researchers followed a survival trick from an animal that cannot escape the tide. Their study found that human lung adenocarcinoma cells can reuse the same energy-stress pathway intertidal oysters use to keep producing fuel, helping sustain malignant growth.

The pathway, called KAT2/HDACIIa–PGK–ALDO, acts on glycolysis—the chain of reactions cells use to make energy. Under stress, a shift between the enzymes KAT2 and HDACIIa increases acetylation of PGK, a chemical modification that shields the enzyme from destruction by the ubiquitin-proteasome system, one of the cell’s protein-disposal routes. The protected PGK also binds more strongly to ALDO, another glycolytic enzyme.

PGK then performs an additional activity: it phosphorylates ALDO, modifying it in a way that increases its catalytic efficiency while reducing its removal through chaperone-mediated autophagy, a lysosome-based disposal route. By limiting both systems at once, the cascade both preserves and activates PGK and ALDO. The researchers combined multi-omics data—large-scale molecular measurements—with gene editing and biochemical functional assays to investigate the mechanism.

The evolutionary link is the study’s central clue. Sessile intertidal oysters endure heat, aerial exposure and hypoxia, or low oxygen, and shift toward aerobic glycolysis in a pattern that closely resembles the Warburg effect observed in tumors. In human lung cancer cells, the team reported increased KAT2A and reduced HDAC5, changes associated with persistent hyperacetylation of PGK1-K75 and hyperphosphorylation of ALDOA-S272, supporting proliferation and metastasis.

So what changes in practice? For cancer researchers, an oyster stress-adaptation system offers a mechanism to examine and potentially target tumor metabolism, with PGK and ALDO at its center. But the evidence remains at the laboratory stage: the study demonstrates the pathway in cells and proposes therapeutic targets, not a tested treatment for patients. The work was published in Proceedings of the National Academy of Sciences in 2026.